Coral Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 27, 2025, 2:05 pm

Market Cap	205 Cr.
Current Price	573
High / Low	999/561
Stock P/E	8.28
Book Value	563
Dividend Yield	0.35 %
ROCE	17.4 %
ROE	13.1 %
Face Value	10.0
PEG Ratio	0.68

Quick Insight

Coral Laboratories Ltd, currently priced at ₹571 with a market capitalization of ₹204 crore, presents an intriguing investment opportunity within the pharmaceuticals sector. The company's price-to-earnings ratio of 8.25 suggests it is undervalued compared to industry peers, typically trading at higher multiples. With a return on equity of 13.1% and a return on capital employed of 17.4%, Coral demonstrates solid profitability metrics, although net profit figures and operational margins remain undisclosed. Notably, promoter holding stands at a robust 71.51%, indicating strong insider confidence. Given these factors, investors may find Coral Laboratories a compelling candidate for further investigation, particularly if operational performance improves and financial disclosures become more transparent.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Coral Laboratories Ltd

Competitors of Coral Laboratories Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	140 Cr.	99.0	247/84.3	27.0	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	4.95 Cr.	2.59	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	35.8 Cr.	48.2	94.9/45.2		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	34.2 Cr.	23.3	29.1/13.1	33.5	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,318.57 Cr	1,212.44		52.64	193.83	0.31%	16.63%	15.26%	6.18

All Competitor Stocks of Coral Laboratories Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	20.08	16.25	25.70	24.73	11.44	13.55	23.15	18.08	28.89	31.66	32.23	22.99	28.13
Expenses	19.03	15.52	21.39	23.88	13.52	11.81	17.00	15.98	22.64	20.92	25.72	16.67	25.44
Operating Profit	1.05	0.73	4.31	0.85	-2.08	1.74	6.15	2.10	6.25	10.74	6.51	6.32	2.69
OPM %	5.23%	4.49%	16.77%	3.44%	-18.18%	12.84%	26.57%	11.62%	21.63%	33.92%	20.20%	27.49%	9.56%
Other Income	2.49	2.03	2.21	1.54	1.16	1.29	1.81	1.37	2.00	1.56	2.54	2.52	1.71
Interest	0.05	0.10	0.11	0.11	0.02	0.00	0.00	0.00	0.00	0.03	0.01	0.02	0.04
Depreciation	0.50	0.50	0.50	0.50	0.68	0.55	0.44	0.49	0.50	0.49	0.51	0.50	0.51
Profit before tax	2.99	2.16	5.91	1.78	-1.62	2.48	7.52	2.98	7.75	11.78	8.53	8.32	3.85
Tax %	14.72%	26.39%	17.26%	51.69%	-45.06%	26.21%	20.21%	27.52%	25.16%	25.21%	25.21%	26.08%	26.49%
Net Profit	2.55	1.59	4.89	0.86	-0.89	1.84	6.00	2.16	5.79	8.80	6.38	6.14	2.83
EPS in Rs	7.14	4.45	13.69	2.41	-2.49	5.15	16.79	6.05	16.21	24.63	17.86	17.19	7.92

Last Updated: May 31, 2025, 6:25 am

Below is a detailed analysis of the quarterly data for Coral Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 28.13 Cr.. The value appears strong and on an upward trend. It has increased from 22.99 Cr. (Dec 2024) to 28.13 Cr., marking an increase of 5.14 Cr..
For Expenses, as of Mar 2025, the value is 25.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.67 Cr. (Dec 2024) to 25.44 Cr., marking an increase of 8.77 Cr..
For Operating Profit, as of Mar 2025, the value is 2.69 Cr.. The value appears to be declining and may need further review. It has decreased from 6.32 Cr. (Dec 2024) to 2.69 Cr., marking a decrease of 3.63 Cr..
For OPM %, as of Mar 2025, the value is 9.56%. The value appears to be declining and may need further review. It has decreased from 27.49% (Dec 2024) to 9.56%, marking a decrease of 17.93%.
For Other Income, as of Mar 2025, the value is 1.71 Cr.. The value appears to be declining and may need further review. It has decreased from 2.52 Cr. (Dec 2024) to 1.71 Cr., marking a decrease of 0.81 Cr..
For Interest, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
For Depreciation, as of Mar 2025, the value is 0.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.50 Cr. (Dec 2024) to 0.51 Cr., marking an increase of 0.01 Cr..
For Profit before tax, as of Mar 2025, the value is 3.85 Cr.. The value appears to be declining and may need further review. It has decreased from 8.32 Cr. (Dec 2024) to 3.85 Cr., marking a decrease of 4.47 Cr..
For Tax %, as of Mar 2025, the value is 26.49%. The value appears to be increasing, which may not be favorable. It has increased from 26.08% (Dec 2024) to 26.49%, marking an increase of 0.41%.
For Net Profit, as of Mar 2025, the value is 2.83 Cr.. The value appears to be declining and may need further review. It has decreased from 6.14 Cr. (Dec 2024) to 2.83 Cr., marking a decrease of 3.31 Cr..
For EPS in Rs, as of Mar 2025, the value is 7.92. The value appears to be declining and may need further review. It has decreased from 17.19 (Dec 2024) to 7.92, marking a decrease of 9.27.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:02 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	51	59	77	95	92	91	71	97	76	78	84	115
Expenses	41	47	60	72	77	79	65	81	67	74	67	89
Operating Profit	10	12	16	23	15	12	5	16	8	4	16	26
OPM %	20%	21%	21%	24%	17%	14%	8%	16%	11%	5%	19%	23%
Other Income	1	3	3	3	4	5	6	4	6	7	6	8
Interest	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	3	2	2	2	2	2	2	2	2	2	2
Profit before tax	10	12	17	25	18	16	9	18	12	8	21	32
Tax %	21%	22%	29%	34%	31%	34%	22%	23%	24%	22%	24%	26%
Net Profit	8	10	12	16	12	10	7	14	9	6	16	24
EPS in Rs	22.03	26.79	34.71	45.63	34.85	28.61	19.96	37.93	25.33	18.05	44.20	67.63
Dividend Payout %	9%	9%	9%	11%	6%	7%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	25.00%	20.00%	33.33%	-25.00%	-16.67%	-30.00%	100.00%	-35.71%	-33.33%	166.67%	50.00%
Change in YoY Net Profit Growth (%)	0.00%	-5.00%	13.33%	-58.33%	8.33%	-13.33%	130.00%	-135.71%	2.38%	200.00%	-116.67%

Coral Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	10%
3 Years:	15%
TTM:	37%

Compounded Profit Growth
10 Years:	10%
5 Years:	28%
3 Years:	44%
TTM:	55%

Stock Price CAGR
10 Years:	0%
5 Years:	22%
3 Years:	30%
1 Year:	-20%

Return on Equity
10 Years:	10%
5 Years:	9%
3 Years:	9%
Last Year:	13%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:31 pm

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	4	4	4	4	4	4	4	4	4	4	4	4
Reserves	47	56	67	106	113	110	112	133	152	151	174	198
Borrowings	0	1	0	2	2	1	6	6	6	0	0	4
Other Liabilities	10	12	19	20	22	21	23	25	28	20	28	25
Total Liabilities	60	72	89	131	140	136	144	168	190	174	206	229
Fixed Assets	20	19	18	18	22	23	23	21	24	25	24	23
CWIP	0	0	0	0	0	0	0	0	2	0	0	2
Investments	1	1	5	39	45	28	25	33	46	41	50	52
Other Assets	40	52	67	74	73	84	97	112	118	108	132	152
Total Assets	60	72	89	131	140	136	144	168	190	174	206	229

Below is a detailed analysis of the balance sheet data for Coral Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
For Reserves, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2024) to 198.00 Cr., marking an increase of 24.00 Cr..
For Borrowings, as of Mar 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 4.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be improving (decreasing). It has decreased from 28.00 Cr. (Mar 2024) to 25.00 Cr., marking a decrease of 3.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 229.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2024) to 23.00 Cr., marking a decrease of 1.00 Cr..
For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 2.00 Cr..
For Investments, as of Mar 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Mar 2024) to 52.00 Cr., marking an increase of 2.00 Cr..
For Other Assets, as of Mar 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2024) to 152.00 Cr., marking an increase of 20.00 Cr..
For Total Assets, as of Mar 2025, the value is 229.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..

Notably, the Reserves (198.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	1	0	5	11	13	-1	-4	1	6	13	-5	-1
Cash from Investing Activity +	1	-0	-3	-10	-13	3	-2	-0	-6	-3	1	-0
Cash from Financing Activity +	0	-0	-0	0	-3	-1	4	0	0	-6	0	3
Net Cash Flow	2	-0	2	1	-2	1	-2	1	0	4	-4	1

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	10.00	11.00	16.00	21.00	13.00	11.00	-1.00	10.00	2.00	4.00	16.00	22.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	93	109	152	132	117	125	122	178	148	184	109	123
Inventory Days	124	97	110	110	155	120	116	176	158	169	100	149
Days Payable	97	61	66	80	75	87	91	129	108	81	34	130
Cash Conversion Cycle	120	145	196	162	197	157	146	225	198	272	176	142
Working Capital Days	143	159	202	181	172	168	177	241	202	251	221	183
ROCE %	19%	21%	22%	27%	28%	16%	13%	8%	13%	7%	5%	13%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%
FIIs	0.42%	0.42%	0.14%	0.14%	0.14%	0.14%	0.14%	0.14%	0.14%	0.23%	0.00%	0.00%
Public	28.07%	28.07%	28.34%	28.34%	28.34%	28.35%	28.34%	28.35%	28.35%	28.26%	28.50%	28.49%
No. of Shareholders	4,388	4,317	4,218	4,110	4,046	4,040	3,981	4,005	4,098	3,831	3,949	4,054

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	67.61	44.19	18.04	25.32	37.94
Diluted EPS (Rs.)	67.61	44.19	18.04	25.32	37.94
Cash EPS (Rs.)	73.24	49.72	24.14	30.89	43.49
Book Value[Excl.RevalReserv]/Share (Rs.)	563.19	496.83	433.29	436.81	382.48
Book Value[Incl.RevalReserv]/Share (Rs.)	563.19	496.83	433.29	436.81	382.48
Dividend / Share (Rs.)	1.50	2.00	0.00	0.00	0.00
Revenue From Operations / Share (Rs.)	321.91	234.17	218.66	211.64	270.30
PBDIT / Share (Rs.)	98.94	64.02	29.97	36.47	54.91
PBIT / Share (Rs.)	93.31	58.49	23.87	30.89	49.37
PBT / Share (Rs.)	90.89	58.03	23.02	33.19	49.25
Net Profit / Share (Rs.)	67.61	44.19	18.04	25.32	37.94
PBDIT Margin (%)	30.73	27.33	13.70	17.23	20.31
PBIT Margin (%)	28.98	24.97	10.91	14.59	18.26
PBT Margin (%)	28.23	24.78	10.53	15.67	18.21
Net Profit Margin (%)	21.00	18.87	8.25	11.96	14.03
Return on Networth / Equity (%)	12.00	8.89	4.16	5.79	9.91
Return on Capital Employeed (%)	16.30	11.55	5.24	6.71	12.61
Return On Assets (%)	10.52	7.67	3.69	4.76	8.09
Total Debt / Equity (X)	0.01	0.00	0.00	0.03	0.04
Asset Turnover Ratio (%)	0.52	0.44	0.42	0.42	0.61
Current Ratio (X)	7.07	6.18	10.42	5.13	3.99
Quick Ratio (X)	6.68	5.57	9.36	4.41	3.21
Inventory Turnover Ratio (X)	3.85	2.87	2.68	1.92	2.39
Interest Coverage Ratio (X)	362.17	114356.50	31.63	92.33	461.63
Interest Coverage Ratio (Post Tax) (X)	256.38	79763.50	19.93	58.31	319.93
Enterprise Value (Cr.)	174.27	71.40	41.37	59.77	86.55
EV / Net Operating Revenue (X)	1.52	0.85	0.52	0.79	0.89
EV / EBITDA (X)	4.93	3.12	3.86	4.59	4.41
MarketCap / Net Operating Revenue (X)	2.18	1.59	1.05	1.21	1.19
Price / BV (X)	1.25	0.74	0.52	0.58	0.84
Price / Net Operating Revenue (X)	2.18	1.59	1.05	1.21	1.19
EarningsYield	0.09	0.11	0.07	0.09	0.11

After reviewing the key financial ratios for Coral Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 22, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 21) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
For Diluted EPS (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
For Cash EPS (Rs.), as of Mar 22, the value is 73.24. This value is within the healthy range. It has increased from 49.72 (Mar 21) to 73.24, marking an increase of 23.52.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 563.19. It has increased from 496.83 (Mar 21) to 563.19, marking an increase of 66.36.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 563.19. It has increased from 496.83 (Mar 21) to 563.19, marking an increase of 66.36.
For Dividend / Share (Rs.), as of Mar 22, the value is 1.50. This value is within the healthy range. It has decreased from 2.00 (Mar 21) to 1.50, marking a decrease of 0.50.
For Revenue From Operations / Share (Rs.), as of Mar 22, the value is 321.91. It has increased from 234.17 (Mar 21) to 321.91, marking an increase of 87.74.
For PBDIT / Share (Rs.), as of Mar 22, the value is 98.94. This value is within the healthy range. It has increased from 64.02 (Mar 21) to 98.94, marking an increase of 34.92.
For PBIT / Share (Rs.), as of Mar 22, the value is 93.31. This value is within the healthy range. It has increased from 58.49 (Mar 21) to 93.31, marking an increase of 34.82.
For PBT / Share (Rs.), as of Mar 22, the value is 90.89. This value is within the healthy range. It has increased from 58.03 (Mar 21) to 90.89, marking an increase of 32.86.
For Net Profit / Share (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
For PBDIT Margin (%), as of Mar 22, the value is 30.73. This value is within the healthy range. It has increased from 27.33 (Mar 21) to 30.73, marking an increase of 3.40.
For PBIT Margin (%), as of Mar 22, the value is 28.98. This value exceeds the healthy maximum of 20. It has increased from 24.97 (Mar 21) to 28.98, marking an increase of 4.01.
For PBT Margin (%), as of Mar 22, the value is 28.23. This value is within the healthy range. It has increased from 24.78 (Mar 21) to 28.23, marking an increase of 3.45.
For Net Profit Margin (%), as of Mar 22, the value is 21.00. This value exceeds the healthy maximum of 10. It has increased from 18.87 (Mar 21) to 21.00, marking an increase of 2.13.
For Return on Networth / Equity (%), as of Mar 22, the value is 12.00. This value is below the healthy minimum of 15. It has increased from 8.89 (Mar 21) to 12.00, marking an increase of 3.11.
For Return on Capital Employeed (%), as of Mar 22, the value is 16.30. This value is within the healthy range. It has increased from 11.55 (Mar 21) to 16.30, marking an increase of 4.75.
For Return On Assets (%), as of Mar 22, the value is 10.52. This value is within the healthy range. It has increased from 7.67 (Mar 21) to 10.52, marking an increase of 2.85.
For Total Debt / Equity (X), as of Mar 22, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 21) to 0.01, marking an increase of 0.01.
For Asset Turnover Ratio (%), as of Mar 22, the value is 0.52. It has increased from 0.44 (Mar 21) to 0.52, marking an increase of 0.08.
For Current Ratio (X), as of Mar 22, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.18 (Mar 21) to 7.07, marking an increase of 0.89.
For Quick Ratio (X), as of Mar 22, the value is 6.68. This value exceeds the healthy maximum of 2. It has increased from 5.57 (Mar 21) to 6.68, marking an increase of 1.11.
For Inventory Turnover Ratio (X), as of Mar 22, the value is 3.85. This value is below the healthy minimum of 4. It has increased from 2.87 (Mar 21) to 3.85, marking an increase of 0.98.
For Interest Coverage Ratio (X), as of Mar 22, the value is 362.17. This value is within the healthy range. It has decreased from 114,356.50 (Mar 21) to 362.17, marking a decrease of 113,994.33.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 22, the value is 256.38. This value is within the healthy range. It has decreased from 79,763.50 (Mar 21) to 256.38, marking a decrease of 79,507.12.
For Enterprise Value (Cr.), as of Mar 22, the value is 174.27. It has increased from 71.40 (Mar 21) to 174.27, marking an increase of 102.87.
For EV / Net Operating Revenue (X), as of Mar 22, the value is 1.52. This value is within the healthy range. It has increased from 0.85 (Mar 21) to 1.52, marking an increase of 0.67.
For EV / EBITDA (X), as of Mar 22, the value is 4.93. This value is below the healthy minimum of 5. It has increased from 3.12 (Mar 21) to 4.93, marking an increase of 1.81.
For MarketCap / Net Operating Revenue (X), as of Mar 22, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 21) to 2.18, marking an increase of 0.59.
For Price / BV (X), as of Mar 22, the value is 1.25. This value is within the healthy range. It has increased from 0.74 (Mar 21) to 1.25, marking an increase of 0.51.
For Price / Net Operating Revenue (X), as of Mar 22, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 21) to 2.18, marking an increase of 0.59.
For EarningsYield, as of Mar 22, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 21) to 0.09, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Coral Laboratories Ltd as of July 27, 2025 is: 490.25

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 27, 2025, Coral Laboratories Ltd is Overvalued by 14.44% compared to the current share price 573.00

Intrinsic Value of Coral Laboratories Ltd as of July 27, 2025 is: 550.36

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 27, 2025, Coral Laboratories Ltd is Overvalued by 3.95% compared to the current share price 573.00

Last 5 Year EPS CAGR: 12.26%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 16.00%, which is a positive sign. The company has higher reserves (118.25 cr) compared to borrowings (2.33 cr), indicating strong financial stability. The company has shown consistent growth in sales (82.17 cr) and profit (16.50 cr) over the years.	The stock has a high average Working Capital Days of 191.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 178.00, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Coral Laboratories Ltd:
1. Net Profit Margin: 21%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 16.3% (Industry Average ROCE: 16.63%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 12% (Industry Average ROE: 15.26%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 256.38
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 6.68
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 8.28 (Industry average Stock P/E: 52.64)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Coral Laboratories Ltd. is a Public Limited Listed company incorporated on 06/02/1997 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24231MH1997PLC422233 and registration number is 422233. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 115.01 Cr. and Equity Capital is Rs. 3.57 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	3B, Patanwala Compound, Mumbai Maharashtra 400086	cs@corallab.com http://www.corallab.com

Management
Name	Position Held
Mrs. Sushma Kadkade	Director & CFO
Ms. Pooja Hindia	Independent Director
Dr. Saurabh Shah	Independent Director
Mr. Malay Doshi	Independent Director
Mr. Rajendrasinh Rana	Director
Mr. Girish M Dhameja	Whole Time Director

FAQ

What is the intrinsic value of Coral Laboratories Ltd?

Coral Laboratories Ltd's intrinsic value (as of 27 July 2025) is 490.25 14.44% lower the current market price of 573.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 205 Cr. market cap, FY2025-2026 high/low of 999/561, reserves of 198 Cr, and liabilities of 229 Cr.

What is the Market Cap of Coral Laboratories Ltd?

The Market Cap of Coral Laboratories Ltd is 205 Cr..

What is the current Stock Price of Coral Laboratories Ltd as on 27 July 2025?

The current stock price of Coral Laboratories Ltd as on 27 July 2025 is 573.

What is the High / Low of Coral Laboratories Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Coral Laboratories Ltd stocks is ₹999/561.

What is the Stock P/E of Coral Laboratories Ltd?

The Stock P/E of Coral Laboratories Ltd is 8.28.

What is the Book Value of Coral Laboratories Ltd?

The Book Value of Coral Laboratories Ltd is 563.

What is the Dividend Yield of Coral Laboratories Ltd?

The Dividend Yield of Coral Laboratories Ltd is 0.35 %.

What is the ROCE of Coral Laboratories Ltd?

The ROCE of Coral Laboratories Ltd is 17.4 %.

What is the ROE of Coral Laboratories Ltd?

The ROE of Coral Laboratories Ltd is 13.1 %.

What is the Face Value of Coral Laboratories Ltd?

The Face Value of Coral Laboratories Ltd is 10.0.